SciGen signs US$145m hep B distribution deal
Monday, 10 October, 2005
Singapore-based generics company SciGen (ASX:SIE) has signed a Chinese distribution agreement worth at least US$145 million (AUD$191.6 million) with Hefei Life Science Park Investment & Development (HID) for its hepatitis B product, Sci-B-Vac.
"This is a very significant commercial deal for SciGen," said SciGen CEO Saul Mashaal in a statement. "The sales targets to which HID has agreed are substantive, yet the agreement allows SciGen considerable control over the future of Sci-B-Vac sales and marketing in China."
Under the agreement HID is required to order and pay for a minimum annual quantity of six million doses of Sci-B-Vac, either as dispensed doses or bulk antigen, for a period seven years. Over this period revenues for doses are expected at US$210 million or US$145 if HID chooses to purchase bulk antigen.
Sci-B-Vac is a third generation recombinant hepatitis B vaccine produced in Chinese hampster ovary (CHO) cells (mammalian cell). It contains a mixture of three regions of the hepatitis B virus surface proteins that according to SciGen stimulates a faster immune response than other hepatitis B vaccine presently available.
HID has been appointed as the non-exclusive distributor of Sci-B-Vac to customers in China and SciGen has retained the right to sell the product directly in China or to appoint other distributors.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
